Prils Market Size

  • Report ID: 4109
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT

Prils Market Outlook:

Prils Market size was over USD 2.51 billion in 2025 and is poised to exceed USD 4.67 billion by 2035, witnessing over 6.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.

The growth of the market can be attributed to the increasing prevalence of high blood pressure. Lifestyle modifications and appropriate medication, such as prils, are frequently used to treat the disease.

When more people are diagnosed with hypertension and given prescriptions for blood pressure management, in turn, could increase the demand for market. According to estimates over 69 million senior adults in India are expected to have hypertension by the year 2050.

Factors that are believed to fuel the prils market growth include the rise in the pharmaceutical industry across the globe. As more people gain access to the medication, there may be an increase in demand as a result of greater accessibility and availability of prils in hospitals, pharmacies, and other locations.


Prils Market overview

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.

The global prils market size was worth more than USD 2.51 billion in 2025 and is poised to witness a CAGR of over 6.4%, crossing USD 4.67 billion revenue by 2035.

North America is anticipated to command a 41% share of the Prils Market by 2035, owing to the increasing cases of obesity.

Key players in the market include Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos